作者: Lasse van Geelen , Dieter Meier , Nidja Rehberg , Rainer Kalscheuer
DOI: 10.1007/S00253-018-8843-6
关键词:
摘要: The rise of multidrug resistance in bacteria rendering pathogens unresponsive to many clinical drugs is widely acknowledged and considered a critical global healthcare issue. There broad consensus that novel antibacterial chemotherapeutic options are extremely urgently needed. However, the development pipeline new drug lead structures poorly filled not commensurate with scale problem since pharmaceutical industry has shown reduced interest antibiotic past decades due high economic risks low profit expectations. Therefore, academic research institutions have special responsibility finding treatment for future. In this mini review, we want provide overview different approaches concepts currently pursued field.